Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for prevention of post‑consolidation thrombocytopenia in AML
ChiCTR2600126202Phase 3Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) and Thrombocytopenia comparing Eltrombopag arm with Placebo arm (2 arms). Primary endpoint: Proportion of patients with platelet count ≥ 50 × 10^9/L who are free from platelet transfusion for ≥ 3 consecutive days by day +14. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
eltrombopag
03
Conditions
acute myeloid leukemia (AML)Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600126202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126202.